910605-24-2

Basic information

• Product Name: 4-[4-(2-isopropoxy-phenyl)-piperidin-1-yl]-cyclohexylamine
• Synonyms: 4-[4-(2-isopropoxy-phenyl)-piperidin-1-yl]-cyclohexylamine
• CAS NO: 910605-24-2
• Molecular Weight: 316.487
• Mol File: 910605-24-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-[4-(2-isopropoxy-phenyl)-piperidin-1-yl]-cyclohexylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[4-(2-isopropoxy-phenyl)-piperidin-1-yl]-cyclohexylamine(910605-24-2)
• EPA Substance Registry System: 4-[4-(2-isopropoxy-phenyl)-piperidin-1-yl]-cyclohexylamine(910605-24-2)

Safety Data

• Hazardous Substances Data: 910605-24-2(Hazardous Substances Data)

Upstream product

• 179321-49-4 N-(tert-butoxycarbonyl)-4-aminocyclohexanone 
• 148583-58-8 4-(2-isopropoxy-phenyl)-piperidine 
• 701-07-5 1-bromo-2-isopropoxybenzene 
• 95-56-7 2-hydroxybromobenzene 
• 174822-94-7 C₁₉H₂₉NO₃ 
• 946605-56-7 C₁₉H₂₉NO₄ 
• 910605-23-1 {4-[4-(2-isopropoxy-phenyl)-piperidin-1-yl]-cyclohexyl}-carbamic acid tert-butyl ester 

Downstream Products

• 910605-21-9 JNJ-26218127 
• 910605-22-0 N-trans-{4-[4-(2-isopropoxy-phenyl)-piperidin-1-yl]-cyclohexyl}-3,4-dimethoxy-benzenesulfonamide 

Relevant articles and documents

(Phenylpiperidinyl)cyclohexylsulfonamides: Development of α1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS)

Although α1 adrenergic receptor blockers can be very effective for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS), their usage is limited by CV-related side-effects that are caused by the subtype non-selec

Piperidinyl substituted cyclohexane-1,4-diamines

The present invention relates to piperidine substituted cyclohexane-1,4-diamine compounds of Formula (I) and pharmaceutically acceptable forms thereof, as α1a/α1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as method of treatments.